|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,680.25 SEK | +0.61% |
|
-2.19% | -1.67% |
| 09:08am | The Warsh test |  |
| 08:01am | Big pharma taps UK playbook to pressure European capitals on drug prices | RE |
Evolution of the Average Target: AstraZeneca PLC
Evolution of the Target Price: AstraZeneca PLC
Changes in Analyst Recommendations: AstraZeneca PLC
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +8.31% | |||||
| +7.52% | |||||
| +13.97% | |||||
| +11.35% | |||||
| +2.68% | |||||
| +11.23% | |||||
| +1.42% | |||||
| +23.85% | |||||
| +12.09% | |||||
| Average | +10.27% | |||||
| Weighted average by Cap. | +9.39% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| JEFFERIES | |
| JPMORGAN | Richard Vosser |
| BARCLAYS | James Gordon |
| BERNSTEIN RESEARCH | Justin Smith |
| alphavalue | Abhishek Raval |
| DZ BANK | Elmar Kraus |
| UBS | Matthew Weston |
| William O'Neil & Co. | |
| BERENBERG | |
| Morgan Stanley | |
| SB1 Markets | |
| Shore Capital | |
| Berenberg Bank | |
| Citigroup | |
| GOLDMAN SACHS | Rajan Sharma |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| Morningstar | |
| BNP Paribas | |
| Svenska Handelsbanken | |
| BNP Paribas Exane | |
| AlphaValue/Baader Europe | |
| Carnegie Group | |
| Intron Health | |
| Deutsche Bank Securities | |
| Nordea Bank | |
| HSBC | |
| Stifel Nicolaus | |
| Jefferies & Co. | |
| Bernstein | |
| B. Riley | |
| RBC Capital Markets | |
| BMO Capital | |
| CREDIT SUISSE | Dominic Lunn |
| Argus | |
| Bank of America Securities/Merrill Lynch | |
| Danske Bank Group | |
| Kepler Capital Markets | |
| Kepler Cheuvreux | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| SVB Leerink | |
| Bryan, Garnier & Co. | |
| Societe Generale | |
| Liberum Capital | |
| ODDO BHF | |
| BANK OF AMERICA (BOFA) | Sachin Jain |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Consensus AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
